Literature DB >> 22344541

All-trans retinoic acid inhibits mesangial cell proliferation by up-regulating p21Waf1/Cip1 and p27Kip1 and down-regulating Skp2.

Baofeng Su1, Xiaolan Chen, Chonghui Zhong, Naifeng Guo, Jianghong He, Yaping Fan.   

Abstract

BACKGROUND: The aim of this study was to examine effects of all-trans retinoic acid (ATRA) on rat mesangial cell proliferation, apoptosis and underlying mechanisms.
METHODS: Cultured HBZY-1 rat mesangial cells received the following treatments: group 1: controls (DMSO); group 2: TGF-beta(1) (10 µg/L); groups 3-5: ATRA (0.1, 1.0 and 10 µmol/L) + TGF-beta(1) (10 µg/L). After treatments, the cells were studied by CCK-8 assay, cell cycle assay and TUNEL staining. p21(Waf1/Cip1), p27(Kip1) and Skp2 mRNA levels were measured by real-time PCR. p21(Waf1/Cip1), p27(Kip1) and Skp2 protein levels were detected by Western blot. The localization of p21(Waf1/Cip1) and p27(Kip1) proteins was observed by immunofluorescence and confocal microscopy.
RESULTS: Compared with controls, TGF-beta(1) significantly enhanced proliferation and inhibited apoptosis of mesangial cells. ATRA dose-dependently reversed both TGF-beta(1)-induced decreases in p21(Waf1/Cip1) mRNA and protein levels and p27(Kip1) protein level and increases in Skp2 mRNA and protein levels, and inhibited TGF-beta(1)-induced proliferation through G(1) arrest. Meanwhile, after ATRA treatments, p21(Waf1/Cip1) and p27(Kip1) proteins mainly localized in the nucleus, and their concentrations in cytoplasm decreased.
CONCLUSION: ATRA inhibited TGF-beta(1)-induced mesangial cell proliferation by up-regulating p21(Waf1/Cip1) mRNA and protein levels, and p27(Kip1) protein level, and down-regulating Skp2 mRNA and protein levels, but it had no significant effect on apoptosis in rat mesangial cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344541     DOI: 10.5301/jn.5000090

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  7 in total

1.  The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.

Authors:  Chu-Fang Chou; Yu-Hua Hsieh; Clinton J Grubbs; Venkatram R Atigadda; James A Mobley; Reinhard Dummer; Donald D Muccio; Isao Eto; Craig A Elmets; W Timothy Garvey; Pi-Ling Chang
Journal:  J Dermatol Sci       Date:  2018-03-15       Impact factor: 4.563

2.  Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor β2 Agonist.

Authors:  Steven E Trasino; Xiao-Han Tang; Maria M Shevchuk; Mary E Choi; Lorraine J Gudas
Journal:  J Pharmacol Exp Ther       Date:  2018-07-27       Impact factor: 4.030

3.  Effect of all-trans retinoic acid on the differentiation of U87 glioma stem/progenitor cells.

Authors:  Zhe Shi; Meiqing Lou; Yaodong Zhao; Quanbin Zhang; Daming Cui; Ke Wang
Journal:  Cell Mol Neurobiol       Date:  2013-07-13       Impact factor: 5.046

4.  Inhibition of HDAC enhances STAT acetylation, blocks NF-κB, and suppresses the renal inflammation and fibrosis in Npr1 haplotype male mice.

Authors:  Prerna Kumar; Venkateswara R Gogulamudi; Ramu Periasamy; Giri Raghavaraju; Umadevi Subramanian; Kailash N Pandey
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-31

5.  Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.

Authors:  Y-J Liao; H-Y Bai; Z-H Li; J Zou; J-W Chen; F Zheng; J-X Zhang; S-J Mai; M-S Zeng; H-D Sun; J-X Pu; D Xie
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

6.  Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy.

Authors:  Han Liao; Shan Zhao; Huihui Wang; Yang Liu; Ying Zhang; Guangwei Sun
Journal:  Int J Nanomedicine       Date:  2019-10-01

7.  Synergistic Antiproliferative Effects of All-Trans Retinoic Acid and Paclitaxel on Autosomal Dominant Polycystic Kidney Disease Epithelial Cells.

Authors:  Que Thanh Thanh Nguyen; Thi Xoan Hoang; Hyunjin Ryu; Kook-Hwan Oh; Jae Young Kim
Journal:  Biomed Res Int       Date:  2021-10-06       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.